Close

Array BioPharma (ARRY) Declines; AstraZeneca (AZN) Says Phase 3 SUMIT Study of Selumetinib in Combination with Dacarbazine Misses Primary Endpoint

July 22, 2015 6:46 AM EDT Send to a Friend
AstraZeneca (NYSE: AZN) today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login